Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome

被引：0
|
作者：
Komrokji, Rami S. [1 ]
Al Ali, Najla H. [1 ]
Alrawi, E. [1 ]
Padron, Eric [1 ]
Perkins, Janelle [2 ]
Field, Teresa [1 ]
Lancet, Jeffrey E. [1 ]
List, Alan F. [2 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：745 / 746
页数：2
相关论文
共 50 条
  • [31] 5′-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment
    Breccia, Massimo
    Salaroli, Adriano
    Loglisci, Giuseppina
    Martelli, Maurizio
    D'Elia, Gianna Maria
    Nanni, Mauro
    Mauro, Francesca Romana
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2011, 35 (10) : 1409 - 1411
  • [32] Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure
    Duong, Vu H.
    Lin, Karen
    Reljic, Tea
    Kumar, Ambuj
    Al Ali, Najla H.
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (06): : 711 - 715
  • [33] Therapy-related myelodysplastic syndrome
    Candelaria, Myrna
    Duenas-Gonzalez, Alfonso
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (05) : 655 - 665
  • [34] Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome
    Hashimoto, Miki
    Itonaga, Hidehiro
    Nannya, Yasuhito
    Taniguchi, Hirokazu
    Fukuda, Yuichi
    Furumoto, Takafumi
    Fujioka, Machiko
    Kasai, Sachie
    Taguchi, Masataka
    Taniguchi, Hiroaki
    Sato, Shinya
    Sawayama, Yasushi
    Atogami, Sunao
    Iwasaki, Keisuke
    Hata, Tomoko
    Soda, Hiroshi
    Moriuchi, Yukiyoshi
    Nakata, Koh
    Ogawa, Seishi
    Miyazaki, Yasushi
    INTERNAL MEDICINE, 2020, 59 (08) : 1081 - 1086
  • [35] Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders
    Andrea Tendas
    Maria Felicita Lissia
    Daniela Piccioni
    Liliana Tirimbelli
    Laura Scaramucci
    Marco Giovannini
    Teresa Dentamaro
    Alessio Perrotti
    Paolo de Fabritiis
    Pasquale Niscola
    Supportive Care in Cancer, 2015, 23 : 303 - 305
  • [36] Activity of Hypomethylating Agents in the Treatment of Therapy-Related Myelodysplastic Syndrome
    Pierola, Ana Alfonso
    Montalban-Bravo, Guillermo
    Takahashi, Koichi
    Feng Wang
    Song Xingzhi
    Jabbour, Elias J.
    Kadia, Tapan M.
    Ravandi, Farhad
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Daver, Naval G.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Konopleva, Marina
    Bueso-Ramos, Carlos E.
    Patel, Keyur
    Futreal, Andrew
    Pierce, Sherry
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2016, 128 (22)
  • [37] THERAPY-RELATED MYELODYSPLASTIC SYNDROME FOLLOWING TREATMENT FOR MALIGNANT GLIOMA
    Sakai, Keiichi
    Tada, Tsuyshi
    Hongo, Kazuhiro
    NEURO-ONCOLOGY, 2009, 11 (06) : 949 - 950
  • [38] Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders
    Tendas, Andrea
    Lissia, Maria Felicita
    Piccioni, Daniela
    Tirimbelli, Liliana
    Scaramucci, Laura
    Giovannini, Marco
    Dentamaro, Teresa
    Perrotti, Alessio
    de Fabritiis, Paolo
    Niscola, Pasquale
    SUPPORTIVE CARE IN CANCER, 2015, 23 (02) : 303 - 305
  • [39] Treatment of myelodysplastic syndromes with azacitidine and thalidomide
    Kenealy, M. K.
    Seymour, J. F.
    LEUKEMIA RESEARCH, 2007, 31 : S7 - S8
  • [40] The role of azacitidine in the treatment of myelodysplastic syndromes
    Abdulhaq, Haifaa
    Rossetti, James M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (12) : 1967 - 1975
12345